Reduction of heavy menstrual bleeding in women not designated as responders to elagolix plus add back therapy for uterine fibroids

EA Stewart, DF Archer, CD Owens… - Journal of Women's …, 2022 - liebertpub.com
Objective: To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual
bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 …
被引用次数：4 相关文章

Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids.

EA Stewart, DF Archer, CD Owens… - Journal of Women's …, 2021 - europepmc.org
Objective: To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual
bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 …

Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids

EA Stewart, DF Archer, CD Owens… - Journal of …, 2022 - scholars.northwestern.edu
Objective: To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual
bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 …
[HTML] nih.gov

[HTML][HTML] Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids

EA Stewart, DF Archer, CD Owens… - Journal of Women's …, 2022 - ncbi.nlm.nih.gov
Objective: To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual
bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 …

Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids

EA Stewart, DF Archer, CD Owens… - Journal of …, 2022 - mayoclinic.elsevierpure.com
Objective: To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual
bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 …

Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids.

EA Stewart, DF Archer, CD Owens… - Journal of Women's …, 2022 - search.ebscohost.com
Objective: To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual
bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 …

Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids

EA Stewart, DF Archer, CD Owens, KT Barnhart… - 2022 - pubmed.ncbi.nlm.nih.gov
Objective: To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual
bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 …